用贝司他汀对成人急性非淋巴细胞白血病进行免疫治疗。
Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults.
作者信息
Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N
出版信息
Cancer Immunol Immunother. 1986;23(1):5-10. doi: 10.1007/BF00205548.
In a cooperative randomized control study of immunotherapy with bestatin in combination with chemotherapy in adults with acute nonlymphocytic leukemia (ANLL), 101 patients (48 in the bestatin group and 53 in the control group) out of 115 patients registered were evaluated as eligible. The bestatin group achieved a statistically significant prolongation of survival compared with the control group in overall ANLL and acute myelogenous leukemia. In the analysis of patient age, the bestatin group achieved a statistically significant prolongation of both the remission duration and survival in patients aged 50 to 65 years, while the differences were not significant in the 15 to 49 age group. The bestatin group tended to achieve a higher rate of reinduction of remission in patients who had recurrence of leukemia. Side effects developed in only 5 (9.6%) of 52 patients treated with bestatin. None of these side effects were particularly serious in nature. It is concluded that bestatin is useful for prolongation of survival of adult patients with ANLL, making for a longer remission duration especially in elderly patients and with few side effects.
在一项关于贝司他汀联合化疗对成人急性非淋巴细胞白血病（ANLL）进行免疫治疗的合作随机对照研究中，登记的115例患者中有101例（贝司他汀组48例，对照组53例）被评估为符合条件。在总体ANLL和急性髓性白血病中，贝司他汀组与对照组相比，生存期有统计学意义的延长。在患者年龄分析中，贝司他汀组在50至65岁患者中，缓解期和生存期均有统计学意义的延长，而在15至49岁年龄组中差异不显著。贝司他汀组在白血病复发患者中倾向于获得更高的再诱导缓解率。接受贝司他汀治疗的52例患者中仅5例（9.6%）出现副作用。这些副作用均无特别严重的性质。结论是，贝司他汀有助于延长成人ANLL患者的生存期，尤其可使老年患者缓解期更长且副作用少。
Zotero 插件